• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

糖尿病预防试验1型参与者中的血糖异常事件及进展为1型糖尿病的情况

Incident dysglycemia and progression to type 1 diabetes among participants in the Diabetes Prevention Trial-Type 1.

作者信息

Sosenko Jay M, Palmer Jerry P, Rafkin-Mervis Lisa, Krischer Jeffrey P, Cuthbertson David, Mahon Jeffery, Greenbaum Carla J, Cowie Catherine C, Skyler Jay S

机构信息

Division of Endocrinology, University of Miami, Miami, Florida, USA.

出版信息

Diabetes Care. 2009 Sep;32(9):1603-7. doi: 10.2337/dc08-2140. Epub 2009 Jun 1.

DOI:10.2337/dc08-2140
PMID:19487644
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC2732147/
Abstract

OBJECTIVE

We studied the incidence of dysglycemia and its prediction of the development of type 1 diabetes in islet cell autoantibody (ICA)-positive individuals. In addition, we assessed whether dysglycemia was sustained.

RESEARCH DESIGN AND METHODS

Participants (n = 515) in the Diabetes Prevention Trial-Type 1 (DPT-1) with normal glucose tolerance who underwent periodic oral glucose tolerance tests (OGTTs) were followed for incident dysglycemia (impaired fasting glucose, impaired glucose tolerance, and/or high glucose levels at intermediate time points of OGTTs). Incident dysglycemia at the 6-month visit was assessed for type 1 diabetes prediction.

RESULTS

Of 515 participants with a normal baseline OGTT, 310 (60%) had at least one episode of dysglycemia over a maximum follow-up of 7 years. Dysglycemia at the 6-month visit was highly predictive of the development of type 1 diabetes, both in those aged <13 years (P < 0.001) and those aged > or =13 years (P < 0.01). Those aged <13 years with dysglycemia at the 6-month visit had a high cumulative incidence (94% estimate by 5 years). Among those who developed type 1 diabetes after a dysglycemic OGTT and who had at least two OGTTs after the dysglycemic OGTT, 33 of 64 (52%) reverted back to a normal OGTT. However, 26 (79%) of the 33 then had another dysglycemic OGTT before diagnosis.

CONCLUSIONS

ICA-positive individuals with normal glucose tolerance had a high incidence of dysglycemia. Incident dysglycemia in those who are ICA positive is strongly predictive of type 1 diabetes. Children with incident dysglycemia have an especially high risk. Fluctuations in and out of the dysglycemic state are not uncommon before the onset of type 1 diabetes.

摘要

目的

我们研究了胰岛细胞自身抗体(ICA)阳性个体中血糖异常的发生率及其对1型糖尿病发生的预测作用。此外,我们评估了血糖异常是否持续存在。

研究设计与方法

对糖尿病预防试验1型(DPT-1)中515名糖耐量正常且接受定期口服葡萄糖耐量试验(OGTT)的参与者进行随访,观察血糖异常(空腹血糖受损、糖耐量受损和/或OGTT中间时间点血糖水平升高)的发生情况。评估6个月随访时的血糖异常情况对1型糖尿病的预测作用。

结果

在515名基线OGTT正常的参与者中,310名(60%)在最长7年的随访中至少有一次血糖异常发作。6个月随访时的血糖异常对1型糖尿病的发生具有高度预测性,在年龄<13岁的人群中(P<0.001)以及年龄≥13岁的人群中(P<0.01)均如此。6个月随访时血糖异常的<13岁人群累积发病率较高(5年估计为94%)。在血糖异常OGTT后发生1型糖尿病且在血糖异常OGTT后至少进行了两次OGTT的人群中,64名中有

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6721/2732147/4dac351e82bb/zdc0090977180002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6721/2732147/0d28addfda73/zdc0090977180001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6721/2732147/4dac351e82bb/zdc0090977180002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6721/2732147/0d28addfda73/zdc0090977180001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6721/2732147/4dac351e82bb/zdc0090977180002.jpg

相似文献

1
Incident dysglycemia and progression to type 1 diabetes among participants in the Diabetes Prevention Trial-Type 1.糖尿病预防试验1型参与者中的血糖异常事件及进展为1型糖尿病的情况
Diabetes Care. 2009 Sep;32(9):1603-7. doi: 10.2337/dc08-2140. Epub 2009 Jun 1.
2
Increasing the accuracy of oral glucose tolerance testing and extending its application to individuals with normal glucose tolerance for the prediction of type 1 diabetes: the Diabetes Prevention Trial-Type 1.提高口服葡萄糖耐量试验的准确性,并将其应用扩展至糖耐量正常个体以预测1型糖尿病:糖尿病预防试验-1型。
Diabetes Care. 2007 Jan;30(1):38-42. doi: 10.2337/dc06-1615.
3
Dysglycemia and Index60 as Prediagnostic End Points for Type 1 Diabetes Prevention Trials.血糖异常与指数60作为1型糖尿病预防试验的诊断前终点
Diabetes Care. 2017 Nov;40(11):1494-1499. doi: 10.2337/dc17-0916. Epub 2017 Aug 31.
4
Use of the Diabetes Prevention Trial-Type 1 Risk Score (DPTRS) for improving the accuracy of the risk classification of type 1 diabetes.使用1型糖尿病预防试验风险评分(DPTRS)提高1型糖尿病风险分类的准确性。
Diabetes Care. 2014 Apr;37(4):979-84. doi: 10.2337/dc13-2359. Epub 2014 Feb 18.
5
A risk score for type 1 diabetes derived from autoantibody-positive participants in the diabetes prevention trial-type 1.一项源自糖尿病预防试验1型中自身抗体阳性参与者的1型糖尿病风险评分。
Diabetes Care. 2008 Mar;31(3):528-33. doi: 10.2337/dc07-1459. Epub 2007 Nov 13.
6
One-Hour Oral Glucose Tolerance Tests for the Prediction and Diagnostic Surveillance of Type 1 Diabetes.1 小时口服葡萄糖耐量试验在 1 型糖尿病的预测和诊断监测中的应用。
J Clin Endocrinol Metab. 2020 Nov 1;105(11):e4094-101. doi: 10.1210/clinem/dgaa592.
7
Glucose excursions between states of glycemia with progression to type 1 diabetes in the diabetes prevention trial-type 1 (DPT-1).在糖尿病预防试验-1(DPT-1)中,随着向 1 型糖尿病的进展,血糖状态之间的葡萄糖波动。
Diabetes. 2010 Oct;59(10):2386-9. doi: 10.2337/db10-0534. Epub 2010 Aug 3.
8
Incidence and Predictors of Dysglycemia and Regression to Normoglycemia in Indian Adolescents and Young Adults: 10-Year Follow-Up of the ORANGE Study.印度青少年和年轻人的糖代谢异常发生率及转归正常的预测因素:ORANGE 研究 10 年随访。
Diabetes Technol Ther. 2020 Dec;22(12):875-882. doi: 10.1089/dia.2020.0109. Epub 2020 Jun 12.
9
Trends of earlier and later responses of C-peptide to oral glucose challenges with progression to type 1 diabetes in diabetes prevention trial-type 1 participants.1 型糖尿病预防试验-1 型参与者中,随着向 1 型糖尿病进展,C 肽对口服葡萄糖挑战的早期和晚期反应的趋势。
Diabetes Care. 2010 Mar;33(3):620-5. doi: 10.2337/dc09-1770. Epub 2009 Dec 23.
10
Screening for Glucose Perturbations and Risk Factor Management in Dysglycemic Patients With Coronary Artery Disease-A Persistent Challenge in Need of Substantial Improvement: A Report From ESC EORP EUROASPIRE V.筛查伴冠状动脉疾病的糖代谢紊乱患者的血糖紊乱和危险因素管理:需要大幅改善的持续挑战:ESC EORP EUROASPIRE V 报告
Diabetes Care. 2020 Apr;43(4):726-733. doi: 10.2337/dc19-2165. Epub 2020 Feb 20.

引用本文的文献

1
REDEFINING AUTOIMMUNE DISEASES: THE OPPORTUNITY FOR PRECISION AND PREVENTION.重新定义自身免疫性疾病:精准治疗与预防的机遇
Trans Am Clin Climatol Assoc. 2025;135:356-369.
2
The Changing Epidemiology of Type 1 Diabetes: A Global Perspective.1型糖尿病不断变化的流行病学:全球视角
Diabetes Obes Metab. 2025 Jun 19. doi: 10.1111/dom.16501.
3
Postprandial Plasma Glucose.餐后血糖

本文引用的文献

1
Glucose and C-peptide changes in the perionset period of type 1 diabetes in the Diabetes Prevention Trial-Type 1.1型糖尿病预防试验-1中1型糖尿病发病前期的葡萄糖和C肽变化
Diabetes Care. 2008 Nov;31(11):2188-92. doi: 10.2337/dc08-0935. Epub 2008 Jul 23.
2
Update in type 1 diabetes.1型糖尿病的最新进展。
J Clin Endocrinol Metab. 2007 Jul;92(7):2403-7. doi: 10.1210/jc.2007-0339.
3
Prediction and prevention of type 1 diabetes: progress, problems, and prospects.1型糖尿病的预测与预防:进展、问题与前景
Clin Diabetes. 2024 Nov 7;43(1):161-164. doi: 10.2337/cd24-0099. eCollection 2025 Winter.
4
ISPAD Clinical Practice Consensus Guidelines 2024: Screening, Staging, and Strategies to Preserve Beta-Cell Function in Children and Adolescents with Type 1 Diabetes.《国际儿童青少年糖尿病研究学会(ISPAD)2024年临床实践共识指南:1型糖尿病儿童和青少年的筛查、分期及保留β细胞功能的策略》
Horm Res Paediatr. 2024;97(6):529-545. doi: 10.1159/000543035. Epub 2024 Dec 11.
5
2. Diagnosis and Classification of Diabetes: Standards of Care in Diabetes-2025.2. 糖尿病的诊断与分类:《2025年糖尿病防治标准》
Diabetes Care. 2025 Jan 1;48(Supplement_1):S27-S49. doi: 10.2337/dc25-S002.
6
Time to reframe the disease staging system for type 1 diabetes.重新构建 1 型糖尿病疾病分期系统的时机已到。
Lancet Diabetes Endocrinol. 2024 Dec;12(12):924-933. doi: 10.1016/S2213-8587(24)00239-0.
7
Plasma Glucose.血浆葡萄糖
Clin Diabetes. 2024 Aug 7;42(4):574-578. doi: 10.2337/cd24-0074. eCollection 2024 Fall.
8
PRE1BRAZIL Protocol: A Randomized Controlled Trial to Evaluate the Effectiveness and Safety of the DPP-4 Inhibitor Alogliptin in Delaying the Progression of Stage 2 Type 1 Diabetes.PRE1巴西方案:一项评估二肽基肽酶-4抑制剂阿格列汀延缓1型糖尿病2期进展的有效性和安全性的随机对照试验。
Diabetes Metab Syndr Obes. 2024 Feb 21;17:857-864. doi: 10.2147/DMSO.S437635. eCollection 2024.
9
Longitudinal Assessment of Pancreas Volume by MRI Predicts Progression to Stage 3 Type 1 Diabetes.MRI 对胰腺体积的纵向评估可预测 3 期 1 型糖尿病的进展。
Diabetes Care. 2024 Mar 1;47(3):393-400. doi: 10.2337/dc23-1681.
10
2. Diagnosis and Classification of Diabetes: Standards of Care in Diabetes-2024.2. 糖尿病的诊断与分类:《2024年糖尿病医疗护理标准》
Diabetes Care. 2024 Jan 1;47(Suppl 1):S20-S42. doi: 10.2337/dc24-S002.
Clin Pharmacol Ther. 2007 May;81(5):768-71. doi: 10.1038/sj.clpt.6100179. Epub 2007 Mar 28.
4
Increasing the accuracy of oral glucose tolerance testing and extending its application to individuals with normal glucose tolerance for the prediction of type 1 diabetes: the Diabetes Prevention Trial-Type 1.提高口服葡萄糖耐量试验的准确性,并将其应用扩展至糖耐量正常个体以预测1型糖尿病:糖尿病预防试验-1型。
Diabetes Care. 2007 Jan;30(1):38-42. doi: 10.2337/dc06-1615.
5
Pre-type 1 diabetes dysmetabolism: maximal sensitivity achieved with both oral and intravenous glucose tolerance testing.1型糖尿病前期代谢紊乱:口服和静脉葡萄糖耐量试验均达到最大敏感性。
J Pediatr. 2007 Jan;150(1):31-36.e6. doi: 10.1016/j.jpeds.2006.09.033.
6
Progression to type 1 diabetes in islet cell antibody-positive relatives in the European Nicotinamide Diabetes Intervention Trial: the role of additional immune, genetic and metabolic markers of risk.欧洲烟酰胺糖尿病干预试验中胰岛细胞抗体阳性亲属发生1型糖尿病的情况:其他免疫、遗传和代谢风险标志物的作用
Diabetologia. 2006 May;49(5):881-90. doi: 10.1007/s00125-006-0160-4. Epub 2006 Mar 3.
7
Patterns of metabolic progression to type 1 diabetes in the Diabetes Prevention Trial-Type 1.1型糖尿病预防试验中向1型糖尿病进展的代谢模式
Diabetes Care. 2006 Mar;29(3):643-9. doi: 10.2337/diacare.29.03.06.dc05-1006.
8
Natural history of beta-cell function in type 1 diabetes.1型糖尿病中β细胞功能的自然史。
Diabetes. 2005 Dec;54 Suppl 2:S32-9. doi: 10.2337/diabetes.54.suppl_2.s32.
9
Effects of oral insulin in relatives of patients with type 1 diabetes: The Diabetes Prevention Trial--Type 1.口服胰岛素对1型糖尿病患者亲属的影响:糖尿病预防试验——1型。
Diabetes Care. 2005 May;28(5):1068-76. doi: 10.2337/diacare.28.5.1068.
10
Insulin secretion in type 1 diabetes.1型糖尿病中的胰岛素分泌。
Diabetes. 2004 Feb;53(2):426-33. doi: 10.2337/diabetes.53.2.426.